Testosterone for Menopause: Evidence and Benefits

Key Takeaways: Menopause reduces testosterone levels by 50% or more, contributing to low libido, fatigue, and body composition changes that estrogen alone does not fix. The 2019 Global Consensus Position Statement supports testosterone therapy for postmenopausal women with HSDD. At physiological doses, testosterone complements estradiol and progesterone as part of a comprehensive HRT approach.

How Menopause Affects Testosterone

The conversation about menopause hormones typically centers on estrogen and progesterone. Testosterone gets left out, which is a significant oversight.

Here is what happens to testosterone through the menopausal transition:

The Decline Timeline

• Ages 20-30: Peak testosterone production. Total T typically 40-60 ng/dL.
• Ages 30-40: Gradual decline begins. Ovarian and adrenal production both decrease. Total T drops to 25-45 ng/dL.
• Ages 40-50 (Perimenopause): Decline accelerates. Irregular ovarian function reduces testosterone output. Total T may fall to 15-30 ng/dL.
• Post-menopause: Ovarian testosterone production drops significantly but does not cease entirely (the ovarian stroma continues to produce some testosterone). Adrenal production also declines. Total T often falls below 20 ng/dL.

Surgical Menopause: A Special Case

Women who undergo bilateral oophorectomy (removal of both ovaries) experience an immediate 50% drop in testosterone, because the ovaries are responsible for roughly half of direct testosterone production and a significant portion of the precursors that peripheral tissues convert.

This sudden drop produces more severe symptoms than natural menopause, where the decline is gradual. Women who have had oophorectomy are among the strongest candidates for testosterone replacement.

The Gap That Estrogen Does Not Fill

Estrogen replacement therapy (ERT) or combined estrogen-progesterone therapy (HRT) effectively treats many menopausal symptoms: hot flashes, night sweats, vaginal dryness, and bone loss. But some symptoms persist even with optimized estrogen.

Women on ERT who still experience:

• Low or absent libido
• Persistent fatigue despite adequate estrogen levels
• Loss of motivation and drive
• Continued muscle wasting and body composition decline
• Brain fog that estrogen did not resolve

These residual symptoms often respond to testosterone replacement. Testosterone and estrogen address different receptor systems and physiological pathways. They are complementary, not redundant.

The Global Consensus Position Statement

In 2019, a Global Consensus Position Statement on the use of testosterone therapy for women was published in the Journal of Clinical Endocrinology and Metabolism. This was co-authored by representatives from eleven international medical societies.

Key Conclusions

1. Testosterone therapy is recommended for postmenopausal women with HSDD after other causes have been excluded
2. Only physiological doses should be used -- formulations that achieve testosterone levels within the premenopausal range
3. A 6-month trial is recommended to assess response
4. Compounded testosterone is acceptable when approved formulations are unavailable (which is the case in the US)
5. Monitoring should include testosterone levels, lipids, and assessment for androgenic side effects

What the Consensus Did Not Endorse

• Testosterone for premenopausal women (insufficient evidence at the time)
• Testosterone for any indication other than HSDD (though many clinicians use it more broadly)
• Supraphysiological dosing
• DHEA as a substitute for testosterone (unpredictable conversion rates)

NAMS Guidelines

The North American Menopause Society (NAMS) has been more conservative. Their 2022 position acknowledges:

• Testosterone may benefit postmenopausal women with HSDD
• There is no FDA-approved testosterone product for women
• Off-label use of approved products or compounded formulations is the current approach
• More research is needed on long-term safety

The practical difference between the Global Consensus and NAMS positions is mainly one of enthusiasm. Both support testosterone use for HSDD in postmenopausal women, but the Global Consensus is more explicitly encouraging.

Benefits of Testosterone in Menopause

Sexual Function

The strongest evidence supports testosterone for sexual desire. The Davis et al. 2019 Lancet meta-analysis found:

• Significant improvement in sexual desire
• Significant improvement in arousal
• Significant improvement in orgasm
• Significant improvement in overall satisfaction
• Reduction in sexually related personal distress

The effect sizes are clinically meaningful. Women reported on average 1-2 additional satisfying sexual events per month, with improvements in desire and arousal that they rated as significant.

Energy and Vitality

While less rigorously studied than sexual function, clinical experience consistently shows energy improvement with testosterone optimization. Testosterone supports mitochondrial function, red blood cell production, and overall metabolic efficiency.

Body Composition

Postmenopausal women lose muscle mass at an accelerated rate. Testosterone helps preserve lean tissue and can promote modest fat loss, particularly visceral (abdominal) fat. This has downstream metabolic benefits: more muscle means better insulin sensitivity and higher resting metabolic rate.

Mood and Cognitive Function

Testosterone acts on androgen receptors in the brain's limbic system and prefrontal cortex. Postmenopausal women receiving testosterone report improvements in mood, motivation, and mental clarity. The research here is emerging but consistent with the neurobiological mechanisms.

Bone Density

Testosterone works alongside estrogen to maintain bone mineral density. For postmenopausal women already on estrogen therapy, adding testosterone provides additional bone protection. For women who cannot or choose not to take estrogen, testosterone offers some degree of bone support, though not as strong as estrogen alone.

Testosterone as Part of Comprehensive HRT

The most effective menopausal hormone therapy addresses all three major hormones:

Hormone	Primary benefits	Delivery methods
Estradiol	Hot flashes, night sweats, vaginal health, bone density, cardiovascular protection	Patch, cream, gel, pellet
Progesterone	Endometrial protection (if uterus present), sleep, anxiety reduction	Oral (micronized), vaginal
Testosterone	Libido, energy, muscle mass, motivation, cognitive clarity	Cream, gel, pellet

The order of optimization typically follows:

1. Estradiol first -- stabilize vasomotor symptoms and establish baseline
2. Progesterone -- add if uterus is present, or for sleep/mood benefits
3. Testosterone -- add after 2-3 months if residual symptoms persist, especially low libido and fatigue

This staged approach helps identify which hormone is responsible for which improvement and avoids changing too many variables at once.

Practical Protocols

Starting Testosterone in Menopause

Prerequisites:

• Already on stable estrogen therapy (preferred but not mandatory)
• Blood work showing low testosterone (total T below 25 ng/dL or free T below the lab's reference midpoint)
• Symptoms consistent with testosterone deficiency
• No contraindications

Initial protocol:

• Testosterone cream 5 mg/day or gel 5 mg/day applied to inner thigh
• Symptom diary tracking libido, energy, mood, sleep, and any side effects
• Blood work at 6-8 weeks: total T, free T, SHBG, estradiol, CBC

Adjustment:

• Target: total T 50-70 ng/dL
• Increase by 2.5 mg/day if levels and symptoms warrant
• Most women stabilize at 5-10 mg/day

Monitoring Schedule

• 6-8 weeks after starting: labs + symptom review
• 6 months: comprehensive evaluation per Global Consensus recommendation
• Every 6-12 months thereafter: labs, symptom assessment, side effect check
• A provider who follows this schedule is essential -- see our independently scored clinic comparison

Addressing Common Concerns

Will Testosterone Make Me Masculine?

At physiological doses (5-10 mg/day topical), masculinizing effects are rare and generally mild. Some women experience slight acne or fine hair growth that resolves with dose adjustment. Voice deepening and significant hirsutism are associated with supraphysiological dosing and should not occur at replacement doses.

Is It Safe Long-Term?

The 2019 meta-analysis found no increase in cardiovascular events, breast cancer, or liver problems in trials lasting up to 24 months. Longer-term data is limited, which is why ongoing monitoring is important. The safety profile at physiological doses is reassuring.

Why Does My Doctor Not Know About This?

Testosterone for women falls into a gap in medical education. Most OB/GYN training focuses on estrogen and progesterone. Endocrinology training focuses on male hypogonadism. The Global Consensus Position Statement is helping close this gap, but awareness varies significantly among providers. Finding a clinic that actively prescribes testosterone for women makes all the difference -- compare options here.

Related Reading

• Testosterone for Perimenopause
• Testosterone for Women: What You Need to Know
• Women's Testosterone Dosage Guide
• Normal vs Optimal Testosterone Levels

---

This content is for informational purposes only and is not medical advice. Consult a qualified healthcare provider before starting any treatment.